
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Michelle Hoiseth, Chief Data Officer for Parexel and Dr. GunjanRead More
The cost of developing a new drug roughly doubles everyRead More
In medicine, a Biomarker is a biological indicator, which canRead More
OntosightⓇ is a discovery platform that leverages proprietary artificial intelligence technologies to generate continuous insights for life sciences. OntosightⓇ Influence is a module of the platform that enables real-time discovery and network analysis of knowledgeable specialists, key opinion leaders (KOLs), and influencers across the entire drug discovery and development value chain, from preclinical to post-launch support.
The AI-based platform automatically identifies top and emerging KOLs based on our integrated and continuously updated data ocean consisting of millions of documents from varied asset classes such as publications, congresses, clinical trials, societies, HTAs, advocacy groups, and many more, to ensure the latest and relevant information.
OntosightⓇ Influence has over 20 million profiles for top and emerging KOLs and influencers including therapeutic area expert (TAEs) and digital opinion leaders (DOLs). The module covers the life science data ocean of Innoplexus to identify influential scientific specialists from upto 95% of world wide web, including sources such as 35M+ publications, 580K+ clinical trial, 3M+ congresses, 35K+ treatment guidelines etc.
Pharmaceutical companies can leverage this module to accelerate discovery of key opinion leaders and influencers for their support in different scientific and commercial activities. Data is updated continuously to enable high accuracy of information driving informed business decisions. The module is highly customizable on logic and scoring to support multiple use cases. Interactive infographics, visualizations, and power-maps enable exploration of networks for chosen therapeutic area. Get up-to-date live update notifications for your favourite KOLs and influencers.
The module can be leveraged for multiple use cases across drug development life cycle.
OntosightⓇ OntosightⓇ Influence uses proprietary algorithms to score TAEs on the basis of any resource category. It features a score equalizer which empowers the user to score the KOLs based on their specific use case and enables customizable weightage for different asset classes such as publications, congresses, clinical trials, guidelines, regulatory bodies, HTA, societies, advocacy or top hospital.
The tool uses proprietary algorithms to score TAEs on the basis of any resource category. The asset classes are scored primarily on 3 parameters – Recency, Quantity and Quality. The KOLs can be further filtered by geography, body names, committee names, speciality, biomarkers, etc.Influence features a score equalizer which empowers the user to score the TAEs / KOLs based on their specific use case. The score equalizer enables customizable weightage for different asset classes such as publications, congresses, clinical trials, guidelines, regulatory bodies, HTA, societies, advocacy or top hospital.
OntosightⓇ Influence allows to deep-dive into TAE / KOL profiles.
The ‘Research Activity’ section which summarizes TAE’s / KOL’s contribution trends for publications, clinical trials, congresses etc. over the time of 5, 10, or 20 years. It also allows to view the overall research interest, such as gene, drug, disease in the form of a word cloud. One can view activity of interest using different resources and details to the original source of the document.
The ‘Network’ tab allows to view connections between chosen KOL and other TAEs /KOLs across the globe. These can be filtered using country.
Moreover, KOLs can be bookmarked. Notifications are generated for new research activity related to the chosen KOLs.
OntosightⓇ Influence is a subscription-based platform. Feel free to contact Innoplexus directly to set up a demo and quote. To know more, click here.
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering to unlock the potential of phytocannabinoids in designing medical therapies. ESCHBORN, Germany,…
https://innoplexus-marketing.s3.amazonaws.com/video/Parexel+Teaser+vParexel.mp4?_=1 Michelle Hoiseth, Chief Data Officer for Parexel and Dr. Gunjan Bhardwaj, CEO Innoplexus discuss the importance of access to the…
The cost of developing a new drug roughly doubles every nine years (inflation-adjusted) aka Eroom’s law. As the volume of data…
In medicine, a Biomarker is a biological indicator, which can mark a state of a biology and is measurable. A…
Featured Blogs …
AI technologies are more widely used in the pharmaceutical industry today to enable for its extensive review of scientific and…